Novel peptide inhibitors of human secretory phospholipase A2 with antiinflammatory activity: Solution structure and molecular modeling

Journal of Medicinal Chemistry

Volumn 50, Issue 24, 2007, Pages 5938-5950

  Thwin, Maung Maung ^a   Satyanarayanajois, Seetharama D ^b   Nagarajarao, Latha M ^a   Sato, Kazuki ^c   Arjunan, Pachiappan ^a   Ramapatna, Satish L ^d   Kumar, Prem V ^a   Gopalakrishnakone, Ponnampalam ^a  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^b UNIVERSITY OF LOUISIANA AT MONROE   (United States)

^c FUKUOKA WOMEN'S UNIVERSITY   (Japan)

^d 1 Gateway Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ASPARTIC ACID; GLYCINE; INTERLEUKIN 1BETA; MATRIX METALLOPROTEINASE; MESSENGER RNA; PHOSPHOLIPASE A2; PHOSPHOLIPASE A2 INHIBITOR; SECRETORY PROTEIN; SYNTHETIC PEPTIDE; TRYPTOPHAN; UNCLASSIFIED DRUG; VALINE; VALYLASPARTYLISOLEUCYLHISTIDYLVALYLTRYPTOPHYLASPARTYLGLYCYLVALYLVALYLASPARTYLISOLEUCYLHISTIDYLVALYLTRYPTOPHYLASPARTYLGLYCYLVALINE;

ANIMAL CELL; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BETA SHEET; CONTROLLED STUDY; DRUG CONFORMATION; DRUG DESIGN; DRUG MECHANISM; DRUG SCREENING; DRUG SYNTHESIS; ENZYME ACTIVITY; HUMAN; HUMAN CELL; IC 50; MOLECULAR MODEL; NONHUMAN; NUCLEOTIDE SEQUENCE; PROTEIN STRUCTURE; RABBIT; RHEUMATOID ARTHRITIS; SYNOVIUM;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ARTHRITIS, RHEUMATOID; CELLS, CULTURED; CIRCULAR DICHROISM; FIBROBLASTS; GENE EXPRESSION; HUMANS; MAGNETIC RESONANCE SPECTROSCOPY; MATRIX METALLOPROTEINASES; MODELS, MOLECULAR; OLIGOPEPTIDES; PEPTIDES; PEPTIDES, CYCLIC; PHOSPHOLIPASES A2, SECRETORY; PROTEIN BINDING; PROTEIN CONFORMATION; RABBITS; SOLUTIONS; STRUCTURE-ACTIVITY RELATIONSHIP; SYNOVIAL FLUID;

EID: 37849012702     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm070385x     Document Type: Article

References (63)

1. Murakami, M.; Kudo, I. Phospholipase A2. J. Biochem. (Tokyo) 2002, 131, 285-292.
2. Triggiani, M.; Granata, F.; Oriente, A.; Gentile, M.; Petraroli, A.; Balestrieri, B.; Marone, G. Secretory phospholipases A2 induce cytokine release from blood and synovial fluid monocytes. Eur. J. Immunol. 2002, 32, 67-76.
3. Pruzanski, W.; Vadas, P. Phospholipase A2: a mediator between proximal and distal effectors of inflammation. Immunol. Today 1991, 12, 143-146.
4. Jamal, O. S.; Conaghan, P. G.; Cunningham, A. M.; Brooks, P. M.; Munro, V. F.; Scott, K. F. Increased expression of human type IIa secretory phospholipase A2 antigen in arthritic synovium. Ann. Rheum. Dis. 1998, 57, 550-558.
5. Pruzanski, W.; Keystone, E. C.; Sternby, B.; Bombardier, C.; Snow, K. M.; Vadas, P. Serum phospholipase A2 correlates with disease activity in rheumatoid arthritis. J. Rheumatol. 1988, 15, 1351-1355.
6. Burrage, P. S.; Mix, K. S.; Brinckerhoff, C. E. Matrix metalloproteinases: role in arthritis. Front Biosci. 2006, 11, 529-543.
7. Konttinen, Y. T.; Ainola, M.; Valleala, H.; Ma, J.; Ida, H.; Mandelin, J.; Kinne, R. W.; Santavirta, S.; Sorsa, T.; Lopez-Otin, C.; Takagi, M. Analysis of 16 different matrix metalloproteinases (MMP-1 to MMP-16) in the synovial membrane: different profiles in trauma and rheumatoid arthritis. Ann. Rheum. Dis. 1999, 58, 691-697.
8. Borkakoti, N. Matrix metalloprotease inhibitors: design from structure. Biochem. Soc. Trans. 2004, 32, 17-20.
9. Lee, C.; Lee, J.; Choi, Y. A.; Kang, S. S.; Baek, S. H. cAMP elevating agents suppress secretory phospholipase A(2)-induced matrix metalloproteinase-2 activation. Biochem. Biophys. Res. Commun. 2006, 340, 1278-1283.
10. Pruzanski, W.; Stefanski, E.; Vadas, P.; McNamara, T. F.; Ramamurthy, N.; Golub, L. M. Chemically modified non-antimicrobial tetracyclines inhibit activity of phospholipases A2. J. Rheumatol. 1998, 25, 1807-1812.
11. Uitto, V. J.; Firth, J. D.; Nip, L.; Golub, L. M. Doxycycline and chemically modified tetracyclines inhibit gelatinase A (MMP-2) gene expression in human skin keratinocytes. Ann. N. Y. Acad. Sci. 1994, 732, 140-151.
12. Gu, Y.; Lee, H. M.; Golub, L. M.; Sorsa, T.; Konttinen, Y. T.; Simon, S. R. Inhibition of breast cancer cell extracellular matrix degradative activity by chemically modified tetracyclines. Ann. Med. 2005, 37, 450-460.
13. Thwin, M. M.; Ong, W. Y.; Fong, C. W.; Sato, K.; Kodama, K.; Farooqui, A. A.; Gopalakrishnakone, P. Secretory phospholipase A2 activity in the normal and kainate injected rat brain, and inhibition by a peptide derived from python serum. Exp. Brain Res. 2003, 150, 427-433.
14. Thwin, M. M.; Gopalakrishnakone, P.; Kini, R. M.; Armugam, A.; Jeyaseelan, K. Recombinant antitoxic and antiinflammatory factor from the nonvenomous snake Python reticulatus: phospholipase A2 inhibition and venom neutralizing potential. Biochemistry 2000, 39, 9604-9611.
15. Thwin, M. M.; Douni, E.; Aidinis, V.; Kollias, G.; Kodama, K.; Sato, K.; Satish, R. L.; Mahendran, R.; Gopalakrishnakone, P. Effect of phospholipase A2 inhibitory peptide on inflammatory arthritis in a TNF transgenic mouse model: a time-course ultrastructural study. Arthritis Res. Ther. 2004, 6, R282-294.
16. Perczel, A.; Fasman, G. D. Quantitative analysis of cyclic β-turn models. Protein Sci. 1992, 1, 378-395.
17. Fasman, G. D. Circular Dichroism and the Conformational Analysis of Biomolecules; Plenum Press: New York, 1996.
18. Wüthrich, K. NMR of Proteins and Nucleic Acids; John Wiley & Sons: New York, 1986.
19. Anderson, N. H.; Neidigh, W. J.; Harris, N. S.; Lee, G. M.; Liu, Z.; Tong, H. Extracting Information from the Temperature Gradients of Polypeptide NH Chemical Shifts. 1. The Importance of Conformational Averaging. J. Am. Chem. Soc. 1997, 119, 8547-8561.
20. Wishart, D. S.; Sykes, B. D.; Richards, F. M. The chemical shift index: a fast and simple method for the assignment of protein secondary structure through NMR spectroscopy. Biochemistry 1992, 31, 1647-1651.
21. Rose, G. D.; Gierasch, L. M.; Smith, J. A. Turns in peptides and proteins. Adv. Protein Chem. 1985, 37, 1-97.
22. Schevitz, R. W.; Bach, N. J.; Carlson, D. G.; Chirgadze, N. Y.; Clawson, R. D.; Dillard, S. E.; Draheim, S. E.; Hartley, L. W.; Jones, N. D.; Mihelich, E. D.; Olkowski, J. L.; Snyder, D. W.; Sommers, C.; Wery, J. P. Structure-based design of the first potent and selective inhibitor of human non-pancreatic secretory phospholipase A2. Nature Struct. Biol. 1995, 2, 458-465.
23. Khandare, J. J.; Chandna, P.; Wang, Y.; Pozharov, V. P.; Minko, T. Novel polymeric prodrug with multivalent components for cancer therapy. J. Pharmacol. Exp. Ther. 2006, 317, 929-937.
24. Church, W. B.; Inglis, S. A.; Tseng, A.; Duell, R.; Lei, P. W.; Bryant, K. J.; Scott, K. F. A novel approach to the design of inhibitors of human secreted phospholipase A2 based on native peptide inhibition. J. Biol. Chem. 2001, 276, 33156-33164.
25. Hruby, V. J.; Al-Obeidi, F.; Kazmierski, W. Emerging approaches in the design of receptor-selective peptide ligands: conformational topographical and dynamic considerations. Biochem. J. 1990, 268, 249-262.
26. Hetenyi, C.; Spoel, D. V. Efficient docking of peptides to proteins without prior knowledge of the binding site. Protein Sci. 2002, 11, 1729-1737.
27. Bayburt, T.; Yu, B.-Z.; Lin, H.-K.; Browning, J.; Jain, M. K.; Gelb, M. H. Human nonpancreatic secreted phospholipase A2: interfacial parameters, substrate specificities, and competitive inhibitors. Biochemistry 1993, 32, 573-582.
28. Dijkstra, B.; Kalk, K.; Hol, W.; Drenth, J. Structure of bovine pancreatic phospholipase A2 at 1.7 A resolution. J. Mol. Biol. 1981, 147, 97-123.
29. Scott, D. L.; Otwinowski, Z.; Gelb, M. H.; Sigler, P. B. Crystal structure of bee-venom phospholipase A2: correction. Science 1991, 252, 764.
30. Chandra, V.; Jast, J.; Kaur, P.; Dey, S.; Perbandt, M.; Srinivasan, A.; Betzel, Ch.; Singh, T. P. Crystal structure of a complex formed between a snake venom phospholipase A2 and a potent peptide inhibitor Phe-Leu-Ser-Tyr-Lys at 1.8 Å resolution. J. Biol. Chem. 2002, 277, 41079-41085.
31. Feldmann, M.; Brennan, F. M.; Maini, R. N. Role of cytokines in rheumatoid arthritis. Annu. Rev. Immunol. 1996, 14, 397-440.
32. Jeong, J. G.; Kim, J. M.; Cho, H.; Hahn, W.; Yu, S. S.; Kim, S. Effects of IL-1beta on gene expression in human rheumatoid synovial fibroblasts. Biochem. Biophys. Res. Commun. 2004, 324, 3-7.
33. Murakami, M.; Kambe, T.; Shimbara, S.; Higashino, K.; Hanasaki, K.; Arita, H.; Horiguchi, M.; Arita, M.; Arai, H.; Inoue, K. et al. Different functional aspects of the group 11 subfamily (types IIA and V) and type X secretory phospholipase A2s in regulating arachidonic acid release and prostaglandin generation: implication of cyclooxygenase-2 induction and phospholipid scramblase-mediated cellular membrane perturbation. J. Biol. Chem. 1999, 274, 31435-31444.
34. Bidgood, M. J.; Jamal, O. S.; Cunningham, A. M.; Brooks, P. M.; Scott, K. F. Type IIA secretory phospholipase A2 up-regulates cyclooxygenase-2 and amplifies cytokine-mediated prostaglandin production in human rheumatoid synoviocytes. J. Immunol. 2000, 165, 2790-2797.
35. Masuda, S.; Murakami, M.; Komiyama, K.; Ishihara, M.; Ishikawa, Y.; Ishii, T.; Kudo, I. Various secretory phospholipase A2 enzymes are expressed in rheumatoid arthritis and augment prostaglandin production in cultured synovial cells. FEBS J. 2005, 272, 655-672.
36. Higashi, S.; Ohishi, H.; Kudo, I. Augmented prostaglandin E2 generation resulting from increased activities of cytosolic and secretory phospholipase A2 and induction of cyclooxygenase-2 in interleukin-1 beta-stimulated rat calvarial cells during the mineralizing phase. Inflamm. Res. 2000, 49, 102-111.
37. Snyder, D. W.; Bach, N. J.; Dillard, R. D.; Draheim, S. E.; Carlson, D. G.; Fox, N.; Roehm, N. W.; Armstrong, C. T.; Chang, C. H.; Hartley, L. W.; Johnson, L. M.; Roman, C. R.; Smith, A. C.; Song, M.; Fleisch, J. H. Pharmacology of LY315920/S-5920, [[3-(aminooxoacetyl)-2-ethyl-1-(phenylmethyl)- 1H-indol-4-yl]oxy] acetate, a potent and selective secretory phospholipase A2 inhibitor: A new class of anti-inflammatory drugs, SPI. J. Pharmacol. Exp. Ther. 1999, 288, 1117-1124.
38. Schwemmer, M.; Aho, H.; Michel, J. B. Interleukin-1beta-induced type IIA secreted phospholipase A2 gene expression and extracellular activity in rat vascular endothelial cells. Tissue Cell 2001, 33, 233-240.
39. Jacques, C.; Béréziat, G.; Humbert, L.; Olivier, J. L.; Corvol, M. T.; Masliah, J.; Berenbaum, F. Posttranscriptional effect of insulin-like growth factor-I on interleukin-1beta-induced type II-secreted phospholipase A2 gene expression in rabbit articular chondrocytes. J. Clin. Invest. 1997, 99, 1864-1872.
40. Touqui, L.; Alaoui-El-Azher, M. Mammalian secreted phospholipases A2 and their pathophysiological significance in inflammatory diseases. Curr. Mol. Med. 2001, 1, 739-754.
41. Beck, S.; Lambeau, G.; Scholz-Pedretti, K.; Gelb, M. H.; Janssen, M. J.; Edwards, S. H.; Wilton, D. C.; Pfeilschifter, J.; Kaszkin, M. Potentiation of tumor necrosis factor alpha-induced secreted phospholipase A2(sPLA2)-IIA expression in mesangial cells by an autocrine loop involving sPLA2 and peroxisome proliferator-activated receptor alpha activation. J. Biol. Chem. 2003, 278, 29799-29812.
42. Schevitz, R. W.; Bach, N. J.; Carlson, D. G.; Chirgadze, N. Y.; Clawson, D. K.; Dillard, R. D.; Draheim, S. E.; Hartley, L. W.; Jones, N. D; Mihelich, E.D.; et al. Structure-based design of the first potent and selective inhibitor of human non pancreatic secretory phospholipase A2. Nat. Struct. Biol. 1995, 2, 458-465.
43. Smart, B. P.; Pan, Y. H.; Weeks, A. K.; Bollinger, J. G.; Bahnson, B. J.; Gelb, M. H. Inhibition of the complete set of mammalian secreted phospholipases A(2) by indole analogues: a structure-guided study. Bioorg. Med. Chem. 2004, 12, 1737-1749.
44. Westermarck, J.; Kähäri, V. M. Regulation of matrix metalloproteinase expression in tumor invasion. FASEB J. 1999, 13, 781-792.
45. Whitmarsh, A. J.; Davis, R. J. Transcription factor AP-1 regulation by mitogen-activated protein kinase signal transduction pathways. J. Mol. Med. 1996, 74, 589-607.
46. Eberhardt, W.; Huwiler, A.; Beck, K. F.; Walpen, S.; Pfeilschifter, J. Amplification of IL-1 beta-induced matrix metalloproteinase-9 expression by superoxide in rat glomerular mesangial cells is mediated by increased activities of NF-kappa B and activating protein-1 and involves activation of the mitogen-activated protein kinase pathways. J. Immunol. 2000, 165, 5788-5797.
47. Benelli, R.; Venè, R.; Bisacchi, D.; Garbisa, S.; Albini, A. Anti-invasive effects of green tea polyphenol epigallocatechin-3-gallate (EGCG), a natural inhibitor of metallo and serine proteases. Biol. Chem. 2002, 383, 101-105.
48. Firestein, G. S. Mechanisms of tissue destruction and cellular activation in rheumatoid arthritis. Curr. Opin. Rheumatol. 1992, 4, 348-354.
49. Pillinger, M. H.; Rosenthal, P. B.; Tolani, S. N.; Apsel, B.; Dinsell, V.; Greenberg, J.; Chan, E. S.; Gomez, P. F.; Abramson, S. B. Cyclooxygenase-2-derived E prostaglandins down-regulate matrix metalloproteinase-1 expression in fibroblast-like synoviocytes via inhibition of extracellular signal-regulated kinase activation. J. Immunol. 2003, 171, 6080-6089.
50. Attiga, F. A.; Fernandez, P. M.; Weeraratna, A. T.; Manyak, M. J.; Patierno, S. R. Inhibitors of Prostaglandin Synthesis Inhibit Human Prostate Tumor Cell Invasiveness and Reduce the Release of Matrix Metalloproteinases. Cancer Res. 2000, 60, 4629-4637.
51. Pachiappan, A.; Thwin, M. M.; Manikandan, J.; Gopalakrishnakone, P. Glial inflammation and neurodegeneration induced by candoxin, a novel neurotoxin from Bungarus candidus venom: global gene expression analysis using microarray. Toxicon 2005, 46, 883-899.
52. Livak, K. J.; Schmittge, T. D. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 2001, 25, 402-408.
53. Bax, A.; Davis, D. G. MLEV-17-based two-dimensional homonuclear magnetization transfer spectroscopy. J. Magn. Reson. 1985, 65, 355-360.
54. 1H NMR spectra of protein via double quantum filtering. Biochem. Biophys. Res. Commun. 1983, 117, 479-485.
55. Bax, A.; Davis D. G. Practical aspects of two-dimensional transverse NOE spectroscopy. J. Magn. Reson. 1985, 63, 207-213.
56. Kumar, A.; Wagner, G.; Ernst, R. R.; Wuthrich, K. Buildup rates of the nuclear overhauser effect measured by two-dimensional proton magnetic resonance spectroscopy: implications for studies of protein conformation. J. Am. Chem. Soc. 1981, 103, 3654-3658.
57. Sklenar, V. Suppression of Radiation Damping in Multidimensional NMR Experiments Using Magnetic Field Gradients. J. Magn. Reson. A 1995, 114, 132-135.
58. 1H spin-spin coupling constants in proteins. Biochem. Biophys. Res. Commun. 1983, 113, 967-974.
59. Goddard, T. D.; Kneller, D. G. SPARKY3, University of California, San Francisco.
60. Guntert, P.; Mumenthaler, C.; Wuthrich, K. Torsion angle dynamics for NMR structure calculation with the new program DYANA. J. Mol. Biol. 1997, 273, 283-298.
61. Herrmann, T.; Guntert, P.; Wuthrich, K. Protein NMR structure determination with automated NOE assignment using the new software CANDID and the torsion angle dynamics algorithm DYANA. J. Mol. Biol. 2003, 319, 209-227.
62. Sutcliffe, M. J. Structure determination from NMR data II. Computational Approaches. In NMR of Macromolecules: A Practical Approach; Roberts, G. C. K, Ed.; Oxford University Press: New York, 1993; pp 359-390.
63. Morris, G. M.; Goodsell, D. S.; Halliday, R. S.; Huey, R.; Hart, W. E.; Belew, R. K.; Olson, A. J. Automated docking using a Lamarckian genetic algorithm and empirical binding free energy function. J. Comput. Chem. 1998, 19, 1639-1662.